Completed PHASE1 INTERVENTIONAL 3-arm NCT03035370

Viaskin Pertussis Vaccine Trial

A Phase I Dose Escalation Randomized, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Reactivation of Pertussis Toxin Immunity With the Viaskin Epicutaneous Delivery System in Healthy Adults

Sponsor: DBV Technologies

Conditions Whooping Cough

Interventions Boostrix™ Viaskin PT 25 mcg Viaskin PT 50 mcg Viaskin PT Placebo

Updated 7 times since 2017 Last updated: Feb 28, 2020 Started: Sep 5, 2016 Primary completion: Apr 25, 2018 Completion: Apr 25, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Whooping Cough and is currently completed. DBV Technologies leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
Aug 2019 — Apr 2020 [monthly]

Unknown Status PHASE1

Status: Active Not Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Aug 2019 [monthly]

Active Not Recruiting PHASE1
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

DBV Technologies
University Hospital, Geneva

Data source: DBV Technologies

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Geneva, Switzerland